Search

Sotatercept

[L50351] On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).

Relebactam

[label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination product RecarbrioⓇ in July 2019.[L7568]

Liraglutide

[A6932] Liraglutide was granted FDA approval on January 25, 2010.[L6070]

Perfluorohexyloctane

[A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536]

Beremagene geperpavec

Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).

Panobinostat

Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma.

Salmeterol

[A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542]

Nandrolone decanoate

[A233849] Nandrolone decanoate was granted FDA approval on 5 October 1962.[L32564]

Brigatinib

[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]

DL-alpha tocopheryl acetate